- Home
- NPKI vs OMER Comparison
NPKI vs OMER Comparison
Compare NPKI & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- OMER
- Stock Information
- Founded
- NPKI 1932
- OMER 1994
- Country
- NPKI United States
- OMER United States
- Employees
- NPKI N/A
- OMER N/A
- Industry
- NPKI Metal Fabrications
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- NPKI Industrials
- OMER Health Care
- Exchange
- NPKI Nasdaq
- OMER Nasdaq
- Market Cap
- NPKI 634.0M
- OMER 667.0M
- IPO Year
- NPKI N/A
- OMER 2009
- Fundamental
- Price
- NPKI N/A
- OMER $10.31
- Analyst Decision
- NPKI
- OMER Buy
- Analyst Count
- NPKI 0
- OMER 3
- Target Price
- NPKI N/A
- OMER $9.00
- AVG Volume (30 Days)
- NPKI 753.7K
- OMER 1.4M
- Earning Date
- NPKI 02-20-2025
- OMER 11-13-2024
- Dividend Yield
- NPKI N/A
- OMER N/A
- EPS Growth
- NPKI N/A
- OMER N/A
- EPS
- NPKI N/A
- OMER N/A
- Revenue
- NPKI $748,372,000.00
- OMER N/A
- Revenue This Year
- NPKI N/A
- OMER N/A
- Revenue Next Year
- NPKI N/A
- OMER N/A
- P/E Ratio
- NPKI $18.93
- OMER N/A
- Revenue Growth
- NPKI 93.70
- OMER N/A
- 52 Week Low
- NPKI $5.61
- OMER $2.61
- 52 Week High
- NPKI $8.65
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- NPKI N/A
- OMER 58.84
- Support Level
- NPKI N/A
- OMER $7.20
- Resistance Level
- NPKI N/A
- OMER $13.60
- Average True Range (ATR)
- NPKI 0.00
- OMER 1.38
- MACD
- NPKI 0.00
- OMER -0.30
- Stochastic Oscillator
- NPKI 0.00
- OMER 48.59
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.